Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pramipexole Dihydrochloride,Pramipexole DiHCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Chinalink Asia Holdings
Deal Size : $20.0 million
Deal Type : Series B Financing
Details : The proceeds will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : Pramipexole Dihydrochloride,Pramipexole DiHCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Chinalink Asia Holdings
Deal Size : $20.0 million
Deal Type : Series B Financing
A Study to Evaluate in Patients With Parkinsonian Type Disorders
Details : CTC-413 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 25, 2018
Lead Product(s) : CTC-501
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Patients With Major Depressive Disorder
Details : CTC-501 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2018
Lead Product(s) : CTC-501
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
